{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T19:40:15Z","timestamp":1722368415532},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Respiratory Journal"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:p>BACKGROUND: Secondary to phasing out chlorofluorocarbons (CFCs), the fluticasone propionate (FP) pressurized metered\u2010dose inhaler has been formulated in a nonozone\u2010depleting propellant, hydrofluoralkane (HFA) 134a.<\/jats:p><jats:p>OBJECTIVES: To demonstrate equivalent efficacy and safety of FP 200 \u00b5g daily propelled by HFA 134a to FP 200 \u00b5g daily propelled by CFCs 11 and 12 over a four\u2010week treatment period in pediatric asthmatic patients.<\/jats:p><jats:p>METHODS: The study was multinational, randomized, double blind and of parallel group design. Eligible patients aged 16 years and younger were steroid naive or receiving 500 \u00b5g\/day or less of beclomethasone dipropionate, budesonide or flunisolide, or 250 \u00b5g\/day or less of inhaled FP. The primary efficacy variable was mean morning peak expiratory flow with equivalence determined if the 90% CIs for the treatment differences between groups were within \u00b115 L\/min.<\/jats:p><jats:p>RESULTS: Three hundred fifteen patients (mean age 9.3\u00b12.8 years) were randomly assigned; 158 patients received FP HFA 134a and 157 patients received FP CFC. Over the four\u2010week treatment period, mean morning peak expiratory flow increased from baseline in both groups (14 L\/min and 17 L\/min, respectively), with a mean treatment difference of \u20102 L\/min. Equivalence was demonstrated between the groups (90% CI \u20106 to +3 L\/min; P=0.589). Both formulations were well tolerated with no serious drug\u2010related events.<\/jats:p><jats:p>CCONCLUSIONS: FP propelled by HFA 134a has equivalent efficacy and comparable safety to FP propelled by CFC propellants at a microgram equivalent dose in pediatric asthmatic patients.<\/jats:p>","DOI":"10.1155\/2003\/627531","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T08:01:08Z","timestamp":1458028868000},"page":"103-109","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fluticasone Propionate, 100 \u00b5g bid, Using a Non\u2010CFC Propellant, HFA 134a, in Asthmatic Children"],"prefix":"10.1155","volume":"10","author":[{"given":"Brian","family":"Lyttle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarja","family":"Panov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Emeryk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Wixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,5,3]]},"container-title":["Canadian Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2003\/627531.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2003\/627531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T19:04:59Z","timestamp":1722366299000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2003\/627531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1155\/2003\/627531"],"URL":"https:\/\/doi.org\/10.1155\/2003\/627531","archive":["Portico"],"relation":{},"ISSN":["1198-2241","1916-7245"],"issn-type":[{"type":"print","value":"1198-2241"},{"type":"electronic","value":"1916-7245"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2003-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}